John Scholler
Impact in
- Oncology top 0.1%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Immunology top 1%
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
Papers in
- Oncology 67
- CAR-T cell therapy research 61
- Cancer Immunotherapy and Biomarkers 4
- Peptidase Inhibition and Analysis 3
-
- T-cell and B-cell Immunology 4
- Immunotherapy and Immune Responses 4
- Co-authors
- Carl H. June (47 shared papers)Brian Keith (5 shared papers)Sònia Guedan (9 shared papers)Avery D. Posey (8 shared papers)Shannon E. McGettigan (9 shared papers)Michael C. Milone (9 shared papers)Steven Μ. Albelda (8 shared papers)Omkar Uday Kawalekar (6 shared papers)
- Journals
- Blood (16 papers)Molecular and Biochemical Parasitology (7 papers)Cancer Immunology Research (4 papers)Proceedings of the National Academy of Sciences (4 papers)Nature Medicine (3 papers)
- Partner nations
- United StatesFinlandJapan
In The Last Decade
John Scholler
88 papers receiving 11.8k citations
John Scholler's Hit Papers
Peers
Comparison fields: 5 of 99
- Oncology 8.5k
- Immunology 1.6k
- Genetics 285
- Virology 142
- Hematology 389
Countries citing papers authored by John Scholler
This map shows the geographic impact of John Scholler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Scholler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Scholler more than expected).
Fields of papers citing papers by John Scholler
This network shows the impact of papers produced by John Scholler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Scholler. The network helps show where John Scholler may publish in the future.
Co-authors
The 25 scholars most cited alongside John Scholler, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 90 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells Hit paper breakdown → | 2016 | 1044 |
| 2 | Targeting cardiac fibrosis with engineered T cells Hit paper breakdown → | 2019 | 627 |
| 3 | Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity Hit paper breakdown → | 2013 | 581 |
| 4 | Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells Hit paper breakdown → | 2012 | 557 |
| 5 | Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell Hit paper breakdown → | 2018 | 541 |
| 6 | Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma Hit paper breakdown → | 2016 | 519 |
| 7 | Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies Hit paper breakdown → | 2016 | 497 |
| 8 | Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation Hit paper breakdown → | 2018 | 482 |
| 9 | 2015 | 445 | |
| 10 | 2017 | 444 | |
| 11 | PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial Hit paper breakdown → | 2022 | 434 |
| 12 | 2014 | 416 | |
| 13 | 2015 | 393 | |
| 14 | 2010 | 391 | |
| 15 | 2015 | 374 | |
| 16 | Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies Hit paper breakdown → | 2020 | 371 |
| 17 | 2014 | 360 | |
| 18 | 2014 | 291 | |
| 19 | 2015 | 271 | |
| 20 | 2018 | 259 |
About John Scholler
John Scholler is a scholar working on Oncology, Immunology, Epidemiology, Genetics and Public Health, Environmental and Occupational Health, having authored 90 papers that have together received 12.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (61 papers), Trypanosoma species research and implications (6 papers), Research on Leishmaniasis Studies (5 papers), Virus-based gene therapy research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers), T-cell and B-cell Immunology (4 papers), Immunotherapy and Immune Responses (4 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Oncology (8.5k citations), Immunology (1.6k citations), Genetics (285 citations), Virology (142 citations) and Hematology (389 citations). John Scholler has collaborated with scholars based in United States, Finland and Japan. Frequent co-authors include Carl H. June, Brian Keith, Sònia Guedan, Avery D. Posey, Shannon E. McGettigan, Michael C. Milone, Steven Μ. Albelda, Omkar Uday Kawalekar, Yangbing Zhao and Regina M. Young. Their work appears in journals such as Blood, Molecular and Biochemical Parasitology, Cancer Immunology Research, Proceedings of the National Academy of Sciences and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.